Neurocrine Biosciences Inc. (NBIX) reported revenue of $0 for fiscal 2014, the year ended 31 December 2014. Net income was -$61 million, and diluted earnings per share $-0.81. The figures are the company's own, from the 10-K it filed with the SEC on 9 February 2015.
Revenue
$0
FY2009FY2014
Operating margin
n/a
-1701.9% a year earlier
FY2009FY2014
Net income
-$61 million
FY2009FY2014
Diluted EPS
-$0.81
FY2009FY2014
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Revenue
0.0
2.9
53.1
Research and development
46.4
39.2
37.2
+18.3%
Operating income
-64.4
-49.7
1.4
Operating margin
n/a
-1701.9%
2.7%
Income tax
0.0
0.0
0.0
Net income
-60.5
-46.1
5.0
Net margin
n/a
-1579.0%
9.5%
Diluted EPS
-$0.81
-$0.69
$0.08
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Operating cash flow
-47.1
-29.6
-35.3
Capital expenditure
1.6
0.5
1.0
+195.8%
Free cash flow
-48.8
-30.2
-36.3
Free cash flow margin
n/a
-1033.0%
-68.2%
Cash from investing
n/a
5.3
-34.8
Cash from financing
n/a
5.3
83.7
Depreciation and amortisation
0.8
0.7
0.7
+23.2%
Share-based compensation
10.4
6.8
5.5
+52.3%
Diluted shares, weighted
75m
67m
67m
+11.3%
Shares outstanding at period end
76m
67m
66m
+13.5%
Balance sheet
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Shareholders' equity
209
120
154
+73.3%
Debt
0.0
0.0
0.0
Other liabilities
34.3
34.3
41.6
+0.2%
Total liabilities and equity
243
155
196
+57.1%
Fixed assets
2.5
1.8
1.9
+41.6%
Investments
200
101
110
+98.4%
Cash and equivalents
31.0
44.8
63.8
-30.8%
Receivables
n/a
0.0
14.1
Other assets
9.2
7.1
6.5
+29.1%
Total assets
243
155
196
+57.1%
10-K for the year ended 31 December 2014, filed 9 February 2015: the filing.